[go: up one dir, main page]

EA200900934A1 - НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB - Google Patents

НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB

Info

Publication number
EA200900934A1
EA200900934A1 EA200900934A EA200900934A EA200900934A1 EA 200900934 A1 EA200900934 A1 EA 200900934A1 EA 200900934 A EA200900934 A EA 200900934A EA 200900934 A EA200900934 A EA 200900934A EA 200900934 A1 EA200900934 A1 EA 200900934A1
Authority
EA
Eurasian Patent Office
Prior art keywords
independently
heteroaryl
aryl
cycloalkyl
alkyl
Prior art date
Application number
EA200900934A
Other languages
English (en)
Inventor
Иоганн Лебан
Харальд Шмитт
Кристина Зольф
Стефано Пегораро
Андреас Вуцик
Original Assignee
4Сц Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Сц Аг filed Critical 4Сц Аг
Publication of EA200900934A1 publication Critical patent/EA200900934A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям общей формулы (I) и его солям и физиологически функциональным производным, где Rнезависимо представляет собой водород, алкил, циклоалкил, гидроксиалкил, галогеноалкил, галогеноалкилокси, арил, замещенный арил, гетероарил, замещенный гетероарил, арилалкил или замещенный арилалкил; Rнезависимо представляет собой -NRR, (II) или (III); Rнезависимо представляет собой алкил, циклоалкил, алкокси, алкиламин, -ОН, -SH, алкилтио, гидроксиалкил, галогеноалкил, галогеноалкилокси, арил или гетероарил; Rнезависимо представляет собой алкил, циклоалкил, алкокси, алкиламин, алкилтио, гидроксиалкил, галогеноалкил, галогеноалкилокси, арил или гетероарил; Rнезависимо представляет собой Н, COR, COR, SOR, SOR, SOR, алкил, циклоалкил, алкокси, -NH, алкиламин, -NRCOR, галоген, -ОН, -SH, алкилтио, гидроксиалкил, галогеноалкил, галогеноалкилокси, арил или гетероарил; Rнезависимо представляет собой Н, алкил, циклоалкил, -NH, алкиламин, арил или гетероарил; Rнезависимо представляет собой Н, алкил, циклоалкил, алкокси, -ОН, -SH, алкилтио, гидроксиалкил, арил или гетероарил; p равен 0 или 1; q равен 0 или 1; Х представляет собой СО или SO.
EA200900934A 2004-09-20 2005-07-29 НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB EA200900934A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04022363A EP1637529A1 (en) 2004-09-20 2004-09-20 Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US61279404P 2004-09-27 2004-09-27

Publications (1)

Publication Number Publication Date
EA200900934A1 true EA200900934A1 (ru) 2009-12-30

Family

ID=34926626

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900934A EA200900934A1 (ru) 2004-09-20 2005-07-29 НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB

Country Status (6)

Country Link
US (2) US7812041B2 (ru)
EP (2) EP1637529A1 (ru)
CN (1) CN101987847B (ru)
EA (1) EA200900934A1 (ru)
NZ (1) NZ588143A (ru)
ZA (1) ZA200701881B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2837702C2 (ru) * 2019-01-22 2025-04-03 Дзе Роскамп Инститьют Производные аминокислот для лечения воспалительных заболеваний

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749537B1 (en) * 1995-12-14 2004-06-15 Hickman Paul L Method and apparatus for remote interactive exercise and health equipment
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
WO2006062982A2 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) * 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
DE102005033103A1 (de) * 2005-07-15 2007-01-25 Bayer Healthcare Ag Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
CA2635888A1 (en) * 2006-01-04 2007-07-19 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
EP1834954A1 (en) * 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
WO2008127302A2 (en) * 2006-10-27 2008-10-23 Genyous BioMed International, Inc. Compositions for treatment and inhibition of pain
CN101573345A (zh) * 2006-10-31 2009-11-04 先灵公司 作为蛋白激酶抑制剂的2-氨基噻唑-4-甲酰胺
JP5337711B2 (ja) * 2007-01-25 2013-11-06 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性アミド
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
US20080241100A1 (en) * 2007-03-27 2008-10-02 Stefan Strobl Pharmaceutical composition comprising a cytokine
WO2008116919A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine
DE102007047735A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
SI2206707T1 (sl) * 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
US9381168B2 (en) * 2007-11-09 2016-07-05 Catholic University Industry Academy Cooperation Foundation Use of capsiate or dihydrocapsidate
EP2225250A2 (en) * 2007-11-30 2010-09-08 Biota Scientific Management Pty Ltd Bicyclic ppat inhibitors as antibacterial agents
EP2225207A2 (en) * 2007-11-30 2010-09-08 Biota Scientific Management Pty. Ltd. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
WO2009135581A2 (en) * 2008-05-05 2009-11-12 Merck Patent Gmbh Novel nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
LT3289876T (lt) * 2008-06-16 2022-11-10 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2010001366A1 (en) * 2008-07-04 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Piperazines derivatives as proteasome modulators
MX2011004490A (es) * 2008-11-04 2011-07-20 Chemocentryx Inc Moduladores de cxcr7.
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US8431575B2 (en) * 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US9339691B2 (en) 2012-01-05 2016-05-17 Icon Health & Fitness, Inc. System and method for controlling an exercise device
CA2892042C (en) 2012-11-29 2022-06-14 Chemocentryx, Inc. Cxcr7 antagonists
EP2969058B1 (en) 2013-03-14 2020-05-13 Icon Health & Fitness, Inc. Strength training apparatus with flywheel and related methods
EP3086865B1 (en) 2013-12-26 2020-01-22 Icon Health & Fitness, Inc. Magnetic resistance mechanism in a cable machine
WO2015138339A1 (en) 2014-03-10 2015-09-17 Icon Health & Fitness, Inc. Pressure sensor to quantify work
WO2015191445A1 (en) 2014-06-09 2015-12-17 Icon Health & Fitness, Inc. Cable system incorporated into a treadmill
WO2015195965A1 (en) 2014-06-20 2015-12-23 Icon Health & Fitness, Inc. Post workout massage device
US10391361B2 (en) 2015-02-27 2019-08-27 Icon Health & Fitness, Inc. Simulating real-world terrain on an exercise device
AU2016245434B2 (en) * 2015-04-07 2020-10-29 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
US10272317B2 (en) 2016-03-18 2019-04-30 Icon Health & Fitness, Inc. Lighted pace feature in a treadmill
US10493349B2 (en) 2016-03-18 2019-12-03 Icon Health & Fitness, Inc. Display on exercise device
US10625137B2 (en) 2016-03-18 2020-04-21 Icon Health & Fitness, Inc. Coordinated displays in an exercise device
US10671705B2 (en) 2016-09-28 2020-06-02 Icon Health & Fitness, Inc. Customizing recipe recommendations
JP7590084B2 (ja) 2018-12-12 2024-11-26 ケモセントリックス，インコーポレイティド 癌治療のためのｃｘｃｒ７阻害剤
CN109988121B (zh) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 一种阿考替胺衍生物的制备方法
BR112022005728A2 (pt) * 2019-09-26 2022-08-23 Global Alliance For Tb Drug Development Inc Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas
CA3151407A1 (en) * 2019-09-26 2021-04-01 Takushi Kaneko Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
CN113234090B (zh) * 2021-04-23 2022-07-29 中国药科大学 靶向泛素化降解FoxM1的化合物或其可药用的盐、制备方法及用途
CN118020708B (zh) * 2022-11-01 2025-10-10 武汉大学 动物模型的构建方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516777A (fr) 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
FR2270848B1 (ru) 1974-02-05 1978-02-03 Clin Midy
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6624169B1 (en) * 1998-07-20 2003-09-23 Wilex Biotechnology Gmbh Urokinase inhibitors
AUPP570898A0 (en) 1998-09-07 1998-10-01 Rocklea Spinning Mills Pty. Limited Method of dyeing cotton/wool blends
AU1930900A (en) 1998-12-04 2000-06-26 University Of Maryland Biotechnology Institute Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith
ES2223512T3 (es) * 1999-04-27 2005-03-01 Novartis Ag Uso de derivados de acidos 2,4-diamino-3-hidroxicarboxilicos como inhibidores de la proteasoma.
DE19921971A1 (de) 1999-05-12 2000-11-16 Volkswagen Ag Abgasreinigungsvorrichtung mit NO¶x¶-Speicherkatalysator und Vorkatalysator
ES2259617T3 (es) * 1999-11-05 2006-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Compuestos heterociclicos y su aplicacion como medicamentos.
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
SK5982003A3 (en) * 2000-11-16 2004-05-04 Sankyo Co 1-Methylcarbapenem derivatives
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
AU2002248432A1 (en) * 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
DE10208256A1 (de) 2002-02-26 2003-09-04 Bayer Ag Piperidinouracile
US7345078B2 (en) 2002-05-31 2008-03-18 The Board Of Trustees Of Michigan State University NF-κB inhibitors and uses thereof
AU2003255240A1 (en) * 2002-08-09 2004-02-25 Axys Pharmaceuticals Proteasome inhibitors : peptide derivatives having c-terminal heteroaryl groups
AU2003257637A1 (en) 2002-08-23 2004-03-11 Dainippon Pharmaceutical Co., Ltd. Proline derivatives
DE10252102A1 (de) * 2002-11-08 2004-05-27 Merck Patent Gmbh Indolderivate
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP4527729B2 (ja) * 2003-12-08 2010-08-18 エフ．ホフマン−ラ ロシュ アーゲー 新規チアゾール誘導体
DE102004006808A1 (de) 2004-02-11 2005-09-01 Grünenthal GmbH Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
BRPI0516958A (pt) 2004-09-20 2008-03-25 4Sc Ag inibidores da nf-capab heterocìclicos
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) * 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
EP1834954A1 (en) * 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2837702C2 (ru) * 2019-01-22 2025-04-03 Дзе Роскамп Инститьют Производные аминокислот для лечения воспалительных заболеваний

Also Published As

Publication number Publication date
CN101987847A (zh) 2011-03-23
US20100048583A1 (en) 2010-02-25
US7812041B2 (en) 2010-10-12
CN101987847B (zh) 2012-10-10
EP1637529A1 (en) 2006-03-22
ZA200701881B (en) 2008-05-28
NZ588143A (en) 2012-04-27
EP2343293A1 (en) 2011-07-13
US20060069102A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EA200900934A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
EA200700441A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
NL300877I2 (nl) obeticholzuur
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
DK1720881T3 (da) 11-hydroxy-5h-(2,1-c)(1,4)benzodiazepin-5-on-derivater som nøglemellemprodukter i fremstilling afc2-substituerede pyrrolobenzodiazepiner
ATE491703T1 (de) Phthalazinonderivate
WO2002000622A3 (en) Aminoalcohol derivatives
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
AR028647A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano benzoxazol, benzotiazol y bencimidazol, su preparacion y su aplicacion en terapéutica
NO20070289L (no) Alkylsubstituerte indolokinoksaliner
EA200800175A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
DK1202954T3 (da) Nye aminobenzophenoner
NO20064175L (no) Heterosyklisk forbindelse
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
ATE426600T1 (de) 7-phenylpyrazolopyridinverbindungen
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
WO2006029154A3 (en) Novel compounds
EA200801123A1 (ru) Производные 6-гетероарилпиридоиндолона, способ их получения и применение их в терапии
DK1651596T3 (da) Hidtil ukendte derivater af 4,4'-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der omfatter samme